• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Effect of enterokinetic prucalopride on intestinal motility in fast rats.促肠动力药普芦卡必利对禁食大鼠肠道蠕动的影响。
World J Gastroenterol. 2003 Sep;9(9):2065-7. doi: 10.3748/wjg.v9.i9.2065.
2
Effects of the enterokinetic prucalopride (R093877) on colonic motility in fasted dogs.促肠动力药普芦卡必利(R093877)对禁食犬结肠动力的影响。
Neurogastroenterol Motil. 2001 Oct;13(5):465-72. doi: 10.1046/j.1365-2982.2001.00280.x.
3
Cardiovascular effects of cisapride and prucalopride on human 5-HT receptors in transgenic mice.西沙必利和普芦卡必利对转基因小鼠 5-HT 受体的心血管作用。
Naunyn Schmiedebergs Arch Pharmacol. 2018 Sep;391(9):975-985. doi: 10.1007/s00210-018-1519-z. Epub 2018 Jun 9.
4
Intraluminal prucalopride increases propulsive motor activities via luminal 5-HT receptors in the rabbit colon.腔内普芦卡必利通过兔结肠腔内 5-HT 受体增加推进性运动活动。
Neurogastroenterol Motil. 2019 Oct;31(10):e13598. doi: 10.1111/nmo.13598. Epub 2019 Apr 23.
5
Efficacy and tolerability of prucalopride in patients with constipation due to spinal cord injury.普芦卡必利对脊髓损伤所致便秘患者的疗效及耐受性
Scand J Gastroenterol. 2002 Apr;37(4):431-6. doi: 10.1080/003655202317316060.
6
Efficacy and safety of prucalopride in adults and children with chronic constipation.普芦卡必利治疗成人和儿童慢性便秘的疗效与安全性。
Expert Opin Pharmacother. 2015 Feb;16(3):407-16. doi: 10.1517/14656566.2015.996547. Epub 2014 Dec 24.
7
Effects and sites of action of a M1 receptor positive allosteric modulator on colonic motility in rats and dogs compared with 5-HT agonism and cholinesterase inhibition.与 5-HT 激动剂和胆碱酯酶抑制剂相比,M1 受体正变构调节剂对大鼠和犬结肠运动的作用和作用部位。
Neurogastroenterol Motil. 2020 Aug;32(8):e13866. doi: 10.1111/nmo.13866. Epub 2020 Apr 26.
8
Propulsion in guinea pig colon induced by 5-hydroxytryptamine (HT) via 5-HT4 and 5-HT3 receptors.5-羟色胺(5-HT)通过5-HT4和5-HT3受体诱导豚鼠结肠推进运动。
J Pharmacol Exp Ther. 1999 Jan;288(1):93-7.
9
Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans.苯并呋喃5-HT4激动剂普芦卡必利对健康人体结肠转运的选择性刺激作用。
Gut. 1999 May;44(5):682-6. doi: 10.1136/gut.44.5.682.
10
Influence of prucalopride on esophageal secondary peristalsis in reflux patients with ineffective motility.普芦卡必利对动力障碍型胃食管反流无效患者食管继发性蠕动的影响。
J Gastroenterol Hepatol. 2018 Mar;33(3):650-655. doi: 10.1111/jgh.13986.

引用本文的文献

1
Relationship Between Intestinal Slow-waves, Spike-bursts, and Motility, as Defined Through High-resolution Electrical and Video Mapping.通过高分辨率电生理和视频映射定义的肠慢波、棘波爆发与运动之间的关系
J Neurogastroenterol Motil. 2022 Oct 30;28(4):664-677. doi: 10.5056/jnm21183.
2
Preclinical experimental models for assessing laxative activities of substances/products under investigation: a scoping review of the literature.用于评估受试物质/产品缓泻活性的临床前实验模型:文献综述
Am J Transl Res. 2022 Feb 15;14(2):698-717. eCollection 2022.
3
The effects of prucalopride on postoperative ileus in guinea pigs.普芦卡必利对豚鼠术后肠麻痹的影响。
Yonsei Med J. 2013 Jul;54(4):845-53. doi: 10.3349/ymj.2013.54.4.845.
4
Role of prucalopride, a serotonin (5-HT(4)) receptor agonist, for the treatment of chronic constipation.普芦卡必利(一种5-羟色胺(5-HT(4))受体激动剂)在治疗慢性便秘中的作用。
Clin Exp Gastroenterol. 2010;3:49-56. doi: 10.2147/ceg.s8091. Epub 2010 May 24.
5
5-HT4 receptor agonists increase sAPPalpha levels in the cortex and hippocampus of male C57BL/6j mice.5-羟色胺4(5-HT4)受体激动剂可提高雄性C57BL/6j小鼠大脑皮层和海马体中的可溶性淀粉样前体蛋白α(sAPPα)水平。
Br J Pharmacol. 2007 Apr;150(7):883-92. doi: 10.1038/sj.bjp.0707178. Epub 2007 Feb 26.
6
Pathophysiological significance of a reaction in mouse gastrointestinal tract associated with delayed-type hypersensitivity.小鼠胃肠道中与迟发型超敏反应相关的一种反应的病理生理意义。
World J Gastroenterol. 2004 Aug 1;10(15):2254-8. doi: 10.3748/wjg.v10.i15.2254.

本文引用的文献

1
Regulation of the enteric nervous system in the colon of patients with slow transit constipation.慢传输型便秘患者结肠中肠神经系统的调节
Hepatogastroenterology. 2002 Nov-Dec;49(48):1540-4.
2
Prucalopride, a systemic enterokinetic, for the treatment of constipation.普芦卡必利,一种全身性促肠动力药,用于治疗便秘。
Aliment Pharmacol Ther. 2002 Jul;16(7):1347-56. doi: 10.1046/j.1365-2036.2002.01272.x.
3
Irritable bowel syndrome: update on pathogenesis and management.肠易激综合征:发病机制与管理的最新进展
Med Princ Pract. 2002 Jan-Mar;11(1):2-17. doi: 10.1159/000048654.
4
Slow Transit Constipation.慢传输型便秘
Curr Treat Options Gastroenterol. 2002 Aug;5(4):279-283. doi: 10.1007/s11938-002-0050-x.
5
Efficacy and tolerability of prucalopride in patients with constipation due to spinal cord injury.普芦卡必利对脊髓损伤所致便秘患者的疗效及耐受性
Scand J Gastroenterol. 2002 Apr;37(4):431-6. doi: 10.1080/003655202317316060.
6
Effects of prucalopride on colonic transit, anorectal function and bowel habits in patients with chronic constipation.普芦卡必利对慢性便秘患者结肠转运、肛门直肠功能及排便习惯的影响。
Aliment Pharmacol Ther. 2002 Apr;16(4):759-67. doi: 10.1046/j.1365-2036.2002.01210.x.
7
Altered periodic rectal motor activity: a mechanism for slow transit constipation.周期性直肠运动活动改变:慢传输型便秘的一种机制。
Neurogastroenterol Motil. 2001 Dec;13(6):591-8. doi: 10.1046/j.1365-2982.2001.00292.x.
8
The effects of the specific 5HT(4) receptor agonist, prucalopride, on colonic motility in healthy volunteers.特异性5-羟色胺(5HT)4受体激动剂普芦卡必利对健康志愿者结肠动力的影响。
Aliment Pharmacol Ther. 2002 Mar;16(3):603-12. doi: 10.1046/j.1365-2036.2002.01195.x.
9
Review article: the complexity of drug development for irritable bowel syndrome.综述文章:肠易激综合征药物研发的复杂性
Aliment Pharmacol Ther. 2002 Mar;16(3):343-51. doi: 10.1046/j.1365-2036.2002.01185.x.
10
Treatment of GI dysmotility in scleroderma with the new enterokinetic agent prucalopride.使用新型促肠动力药普芦卡必利治疗硬皮病中的胃肠道动力障碍。
Am J Gastroenterol. 2002 Jan;97(1):194-7. doi: 10.1111/j.1572-0241.2002.05396.x.

促肠动力药普芦卡必利对禁食大鼠肠道蠕动的影响。

Effect of enterokinetic prucalopride on intestinal motility in fast rats.

作者信息

Qi Hui-Bin, Luo Jin-Yan, Liu Xin

机构信息

Department of Gastroenterology, Second Hospital of Xi'an Jiaotong University, Xi'an 710004, Shannxi Province, China.

出版信息

World J Gastroenterol. 2003 Sep;9(9):2065-7. doi: 10.3748/wjg.v9.i9.2065.

DOI:10.3748/wjg.v9.i9.2065
PMID:12970907
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4656675/
Abstract

AIM

To evaluate the effects of prucalopride on intestinal prokinetic activity in fast rats and to provide experimental basis for clinical treatment of gastrointestinal motility diseases.

METHODS

Gastrointestinal propulsion rate was measured by the migration rate of activated charcoal, which reflexes gastrointestinal motility function. 120 Spraque-Dawley rats were randomly divided into four groups and received an intravenous injection of physiological saline (served as control), prucalopride 1 mg/kg, prucalopride 2 mg/kg and cisapride 1 mg/kg, respectively. The gastrointestinal propulsion rate was measured 1, 2 or 4 hours after intravenous injection of the drugs.

RESULTS

Significant accelerations of gastrointestinal propulsion rate in prucalopride 1 mg/kg and 2 mg/kg groups were found compared with control group at 2 and 4 hours(83.2 %+/-5.5 %, 81.7 %+/-8.5 % vs 70.5 %+/-9.2 %, P<0.01; 91.2 %+/-2.2 %, 91.3 %+/-3.9 % vs 86.8 %+/-2.6 %, P<0.01). The gastrointestinal propulsion rates at 1, 2 or 4 hours were faster in prucalopride 1 mg/kg and 2 mg/kg groups than in cisapride group (84.0 %+/-11.7 %, 77.1 %+/-11.9 % vs 66.3 %+/-13.6 %, P<0.01, P<0.05; 83.2 %+/-5.5 %, 81.7 %+/- 8.5 % vs 75.4 %+/-5.9 %, P<0.01, P<0.05; 91.2 %+/-2.2 %, 91.3 %+/-3.9 % vs 88.6 %+/-3.5 %,P<0.05, P<0.05). No difference of gastrointestinal propulsion rate was found between prucalopride 1 mg/kg group and prucalopride 2 mg/kg group (P>0.05).

CONCLUSION

Prucalopride accelerates intestinal motility in fast rats, and has no dose dependent effect.

摘要

目的

评价普芦卡必利对禁食大鼠肠道促动力活性的影响,为临床治疗胃肠动力性疾病提供实验依据。

方法

采用活性炭移动率测定胃肠推进率,以反映胃肠动力功能。将120只Spraque-Dawley大鼠随机分为四组,分别静脉注射生理盐水(作为对照组)、1 mg/kg普芦卡必利、2 mg/kg普芦卡必利和1 mg/kg西沙必利。在静脉注射药物后1、2或4小时测量胃肠推进率。

结果

与对照组相比,1 mg/kg和2 mg/kg普芦卡必利组在2小时和4小时时胃肠推进率显著加快(83.2%±5.5%,81.7%±8.5%对70.5%±9.2%,P<0.01;91.2%±2.2%,91.3%±3.9%对86.8%±2.6%,P<0.01)。1 mg/kg和2 mg/kg普芦卡必利组在1、2或4小时时的胃肠推进率比西沙必利组更快(84.0%±11.7%,77.1%±11.9%对66.3%±13.6%,P<0.01,P<0.05;83.2%±5.5%,81.7%±8.5%对75.4%±5.9%,P<0.01,P<0.05;91.2%±2.2%,91.3%±3.9%对88.6%±3.5%,P<0.05,P<0.05)。1 mg/kg普芦卡必利组和2 mg/kg普芦卡必利组之间的胃肠推进率无差异(P>0.05)。

结论

普芦卡必利可加快禁食大鼠的肠道蠕动,且无剂量依赖性效应。